Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-20T17:47:28.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Piloting the development of a cost-effective evidence-informed clinical pathway: Managing hypertension in Jordanian primary care

Published online by Cambridge University Press:  08 April 2011

Kalipso Chalkidou ,
Joanne Lord ,
Nour A. Obeidat ,
Ibriham A. Alabbadi ,
Adrian G. Stanley ,
Rania Bader ,
Aiman Momani ,
Rachel M. O'Mahony ,
Lara Qatami  and
Derek Cutler
Kalipso Chalkidou
Affiliation:
National Institute for Health and Clinical Excellence
Joanne Lord
Affiliation:
Brunel University
Nour A. Obeidat
Affiliation:
King Hussein Institute for Biotechnology and Cancer
Ibriham A. Alabbadi
Affiliation:
University of Jordan
Adrian G. Stanley
Affiliation:
University of Leicester and University Hospitals of Leicester NHS Trust
Rania Bader
Affiliation:
Pharmaceutical Policy Consultant
Aiman Momani
Affiliation:
PharmaNet
Rachel M. O'Mahony
Affiliation:
National Clinical Guidelines Centre, Royal College of Physicians
Lara Qatami
Affiliation:
King Hussein Cancer Center
Derek Cutler
Affiliation:
National Institute for Health and Clinical Excellence
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The UK's National Institute for Health and Clinical Excellence (NICE) and the Jordan office of the Medicines Transparency Alliance embarked on a pilot project to design an evidence-based guideline for cost-effective pharmacological treatment of essential hypertension in Jordan. The project's objectives were to directly address a major health problem for Jordan by producing a guideline; and to delineate the strengths and weaknesses of Jordan's healthcare process to allow similar future efforts to be planned more efficiently.

Methods: The pilot spanned a period of approximately 8 months. Activities were overseen by local technical and guideline development teams, as well as experts from NICE. NICE's hypertension guidelines and economic model were used as a starting point. Parameters in the economic model were adjusted according to input and feedback from local experts with regards to Jordanian physician and patient practices, resource costs, and quality of life estimates. The results of the economic model were integrated with the updated available clinical trial literature.

Results: The outputs of the economic model were used to inform recommendations, in the form of a clinical algorithm. A report of the process and the strengths and weaknesses observed was developed, and recommendations for improvements were made.

Conclusions: The pilot represented the start of what is intended to be a healthcare process change for the country of Jordan. Issues emerged which can inform strategies to ensure a more cohesive and comprehensive approach to the cost-effective use of appropriate drugs in managing chronic disease in Jordan and countries operating in a similarly resource-constrained environment. Furthermore, our pilot highlights how richer countries with relevant experience in evidence-informed healthcare policy making can assist others in strengthening their decision-making methods and processes.

Keywords

HypertensionTreatment guidelinesEvidence-based medicineJordanNICELMIC
Type
METHODS
Information
International Journal of Technology Assessment in Health Care , Volume 27 , Issue 2 , April 2011 , pp. 151 - 158
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Ajlouni, K, Jaddou, H, Batieha, A. Diabetes and impaired glucose tolerance in Jordan: Prevalence and associated risk factors. J Intern Med. 1998;244:317–323.CrossRefGoogle ScholarPubMed
2. Al-Azzam, SI, Najjar, RB, Khadar, YS. Awareness of physicians in Jordan about the treatment of high blood pressure according to the seventh report of the Joint National Committee (JNC VII). Eur J Cardiovasc Nurs. 2007;6:223–232.CrossRefGoogle Scholar
3. Chalkidou, K, Levine, R, Dillon, A. Helping poorer countries make locally informed health decisions. Br Med J. 2010 341:284–286.CrossRefGoogle ScholarPubMed
4. Chobanian, AV, Bakris, GL, Black, HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.CrossRefGoogle ScholarPubMed
5. ESH/ESC Hypertension guidelines committee. Practice guidelines for primary care physicians. 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003;21:1779–1786.Google Scholar
6. High Health Council Jordan. http://www.hhc.gov.jo/HHC/index_e.html (accessed October 18, 2010).Google Scholar
7. International Society for Pharmoeconomics and Outcomes Research. Principles of good practice for decision analytic modeling. http://www.ispor.org/workpaper/research_practices/PrinciplesofGoodPracticeforDecisionAnalyticModelingModelingStudies.pdf.Google Scholar
8. Jamerson, K, Weber, MA, Bakris, GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.CrossRefGoogle ScholarPubMed
9. Joint Procurement Department Jordan. http://images.jordan.gov.jo/wps/wcm/connect/gov/egov/government+ministries+_+entities/joint+procurement+department/general+information/joint+procurement+department+general+information.Google Scholar
10. Jordan Breast Cancer Program. http://www.jbcp.jo/en.Google Scholar
11. Jordan Directorate of Disease Control & Prevention. Survey of prevalence of selected risk factors for chronic disease. Amman, Jordan: Directorate of Disease Control & Prevention; 2007.Google Scholar
12. Jordan Food and Drug Administration website. http://www.jfda.jo/EN/Laws/LawInfo.aspx?id=507.Google Scholar
13. Jordan MeTA Council. Medicines transparency alliance national workplan: Jordan. Amman, Jordan: Jordan MeTA Council; 2008.Google Scholar
14. Lavis, JN, Panisset, U. EVIPNet Africa's first series of policy briefs to support evidence-informed policymaking. Int J Technol Assess Health Care. 2010;26:229–232.CrossRefGoogle ScholarPubMed
15. Marquez, P, Chalkidou, K, Cutler, D, et al. Putting evidence into practice to redesign healthcare: Some lessons for Europe and Central Asia from the United Kingdom. World Bank Knowledge Brief. Washington, DC: World Bank; 2010.Google Scholar
16. Medicine Transparency Alliance website. http://www.medicinestransparency.org/.Google Scholar
17. MeTA Jordan. A model Standard Treatment Guideline (STG) for Essential Hypertension and Improving Rational Use of Medicines in Jordan. http://www.medicinestransparency.org/fileadmin/uploads/Documents/Global_Forum/Global_Forum__-_case_studies/MeTA_Jordan_-_Standard_Treatment_Guidelines.pdf.Google Scholar
18. National Collaborating Centre for Chronic Conditions. Hypertension: Management in adults in primary care: Pharmacological update. London: Royal College of Physicians; 2006.Google Scholar
19. Oxman, A and Hanney, S. SUPPORT Tools for evidence-informed health Policymaking (STP). http://www.health-policy-systems.com/supplements/7/S1CrossRefGoogle Scholar
20. Rational Drug Use Unit, Jordan Food and Drug Administration website. http://www.jfda.jo/RDU/en-US/IndexPage.aspx (accessed October 18, 2010).Google Scholar
21. Venkat Narayan, KM, Ali, M, Koplan, JP. Global Noncommunicable Diseases – Where Worlds Meet. N Engl J Med. 2010;363:1196–1198.CrossRefGoogle Scholar
22. Wiysonge, CSU, Bradley, HA, Mayosi, BM, et al. Beta-blockers for hypertension Cochrane Database Syst Rev. 2010;1:CD002003.Google Scholar
23. World Bank HNPStats. Health, nutrition and population statistics. http://ddp-ext.worldbank.org/ext/ddpreports/ViewSharedReport?&CF=1&REPORT_ID=10309&REQUEST_TYPE=VIEWADVANCED&HF=N.Google Scholar
24. Yusuf, F, Teo, KK, Pogue, J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.Google ScholarPubMed
Supplementary material: Image

Chalkidou supplementary material

Supplementary diagram

Download Chalkidou supplementary material(Image)
Image 508.5 KB